Explore the guide and start building a roadmap to expand access to CGP: https://pcc-cgpimplementationguide.avalerehealth.com/

Comprehensive Genomic Profiling (CGP) identifies the full set of biomarkers needed to guide clinical decision-making. It enables access to approved targeted therapies and clinical trials and is becoming essential in the management of many cancers.

To expand global access to comprehensive genomic testing, the PCC has developed The Pathway to Precision Cancer Care: A Strategic and Operational Guide to Enhance Patient Access to CGP – a practical, system-level resource for health ministries, providers, cancer program leaders, institutions, and consortia seeking to embed CGP into routine cancer care.

Limited CGP capability has significant implications for patients, clinicians, and health systems. Without coordinated action:

• Patient care may suffer, with missed opportunities for accurate diagnosis, targeted therapies, clinical trials, and improved outcomes
• Costs may rise due to inefficient use of testing resources
• Results may be delayed or misinterpreted because of the complexity of genomic data and shortages in specialized expertise
• Patients and families may receive insufficient information, limiting confidence and shared decision-making
• Potential economic benefits are lost as investment in CGP offers the prospect of delivering substantial economic value that extends beyond healthcare alone

By tackling these barriers, health systems can move closer to equitable, sustainable precision oncology for all patients.

Designed for diverse health systems, the guide offers adaptable, actionable steps, practical tools, and real-world examples to help organizations initiate, scale, and strengthen CGP programs. It addresses the critical challenges that currently limit access.

The guide supports implementation across countries and tumor types through three core pillars:

1. System setup
2. Quality assurance
3. Workforce capability

Each pillar addresses key adoption challenges and includes clear milestones, planning tools, and practical examples to help teams assess their current state and build a tailored roadmap to launch, expand, and sustain CGP services.

On an episode of Within Reach, powered by Avalere Health, Andrea Stevens (Interim Head for Global Commercial Precision Medicine at Johnson & Johnson) and Clare Jones (Executive Director for Global Market Access at Avalere Health) discussed the complexities of precision medicine, including financial barriers, geographic disparities, and educational gaps. They both emphasized the need for comprehensive biomarker testing, standardized reporting, and better integration of testing into clinical practice. They also discuss the potential of AI to improve patient outcomes and the importance of global strategies to ensure equitable access to precision medicine.

Listen to the full conversation on Within Reach here: https://bit.ly/promiseofprecisiononcology

PCC-279 | Date: July 2026